Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Over the last 7 days, the market has risen 2.6%, driven by gains in every sector, especially the Industrials sector. As for the past 12 months, the market is up 6.7%. Looking forward, earnings are forecast to grow by 22% annually. Market details ›